Compare IVA & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVA | BRSP |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | France | United States |
| Employees | 77 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.8M | 738.7M |
| IPO Year | N/A | 2017 |
| Metric | IVA | BRSP |
|---|---|---|
| Price | $4.06 | $5.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $16.20 | $6.50 |
| AVG Volume (30 Days) | 466.4K | ★ 849.8K |
| Earning Date | 03-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.03% |
| EPS Growth | N/A | ★ 75.24 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $330,587,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $751.20 | $17.54 |
| P/E Ratio | ★ N/A | $185.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.94 | $4.84 |
| 52 Week High | $7.98 | $6.17 |
| Indicator | IVA | BRSP |
|---|---|---|
| Relative Strength Index (RSI) | 32.13 | 38.68 |
| Support Level | $3.77 | $5.44 |
| Resistance Level | $4.67 | $6.00 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 12.35 | 26.39 |
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.